Cargando…
P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171634/ http://dx.doi.org/10.1097/01.HS9.0000936292.14792.3e |
| _version_ | 1785039463238336512 |
|---|---|
| author | Lowther, D.E. Houseman, E.A. Han, G. Kleanthous, E. Knoblock, D. Zhou, X. Banerjee, S. Patel, S. Figueroa, D. |
| author_facet | Lowther, D.E. Houseman, E.A. Han, G. Kleanthous, E. Knoblock, D. Zhou, X. Banerjee, S. Patel, S. Figueroa, D. |
| author_sort | Lowther, D.E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171634 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101716342023-05-11 P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Lowther, D.E. Houseman, E.A. Han, G. Kleanthous, E. Knoblock, D. Zhou, X. Banerjee, S. Patel, S. Figueroa, D. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171634/ http://dx.doi.org/10.1097/01.HS9.0000936292.14792.3e Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Lowther, D.E. Houseman, E.A. Han, G. Kleanthous, E. Knoblock, D. Zhou, X. Banerjee, S. Patel, S. Figueroa, D. P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | p41 no evidence of b-cell maturation antigen (bcma) expression loss or systemic immune impairment after treatment with the bcma-targeted antibody-drug conjugate belantamab mafodotin in patients with relapsed/refractory multiple myeloma |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171634/ http://dx.doi.org/10.1097/01.HS9.0000936292.14792.3e |
| work_keys_str_mv | AT lowtherde p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT housemanea p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT hang p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT kleanthouse p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT knoblockd p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT zhoux p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT banerjees p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT patels p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma AT figueroad p41noevidenceofbcellmaturationantigenbcmaexpressionlossorsystemicimmuneimpairmentaftertreatmentwiththebcmatargetedantibodydrugconjugatebelantamabmafodotininpatientswithrelapsedrefractorymultiplemyeloma |